Thirty-One Novel Biomarkers as Predictors for Clinically Incident Diabetes
Open Access
- 9 April 2010
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 5 (4), e10100
- https://doi.org/10.1371/journal.pone.0010100
Abstract
The prevalence of diabetes is increasing in all industrialized countries and its prevention has become a public health priority. However, the predictors of diabetes risk are insufficiently understood. We evaluated, whether 31 novel biomarkers could help to predict the risk of incident diabetes. The biomarkers were evaluated primarily in the FINRISK97 cohort (n = 7,827; 417 cases of clinically incident diabetes during the follow-up). The findings were replicated in the Health 2000 cohort (n = 4,977; 179 cases of clinically incident diabetes during the follow-up). We used Cox proportional hazards models to calculate the relative risk of diabetes, after adjusting for the classic risk factors, separately for each biomarker. Next, we assessed the discriminatory ability of single biomarkers using receiver operating characteristic curves and C-statistics, integrated discrimination improvement (IDI) and net reclassification improvement (NRI). Finally, we derived a biomarker score in the FINRISK97 cohort and validated it in the Health 2000 cohort. A score consisting of adiponectin, apolipoprotein B, C-reactive protein and ferritin almost doubled the relative risk of diabetes in the validation cohort (HR per one standard deviation increase 1.88, p = 2.8 e-5). It also improved discrimination of the model (IDI = 0.0149, p<0.0001) and reclassification of diabetes risk (NRI = 11.8%, p = 0.006). Gender-specific analyses suggested that the best score differed between men and women. Among men, the best results were obtained with the score of four biomarkers: adiponectin, apolipoprotein B, ferritin and interleukin-1 receptor antagonist, which gave an NRI of 25.4% (p<0.0001). Among women, the best score included adiponectin, apolipoprotein B, C-reactive protein and insulin. It gave an NRI of 13.6% (p = 0.041). We identified novel biomarkers that were associated with the risk of clinically incident diabetes over and above the classic risk factors. This gives new insights into the pathogenesis of diabetes and may help with targeting prevention and treatment.Keywords
This publication has 33 references indexed in Scilit:
- Development of a Type 2 Diabetes Risk Model From a Panel of Serum Biomarkers From the Inter99 CohortDiabetes Care, 2009
- Sustained Effects of Interleukin-1 Receptor Antagonist Treatment in Type 2 DiabetesDiabetes Care, 2009
- Elevated Levels of the Anti-Inflammatory Interleukin-1 Receptor Antagonist Precede the Onset of Type 2 DiabetesDiabetes Care, 2009
- Full Accounting of Diabetes and Pre-Diabetes in the U.S. Population in 1988–1994 and 2005–2006Diabetes Care, 2009
- Adiponectin and cardiovascular risk prediction: Can the ambiguities be resolved?Nutrition, Metabolism and Cardiovascular Diseases, 2008
- Clinical Risk Factors, DNA Variants, and the Development of Type 2 DiabetesNew England Journal of Medicine, 2008
- Elevated serum ferritin levels predict new-onset type 2 diabetes: results from the EPIC-Norfolk prospective studyDiabetologia, 2007
- Adiponectin and the Development of Type 2 DiabetesDiabetes, 2004
- The Diabetes Risk ScoreDiabetes Care, 2003